Patients diagnosed with hepatitis C who are hepatitis C antibody positive, whether hepatitis C RNA level is measurable or not, must have no evidence of cirrhosis and have liver function tests
Participants with active hepatitis B or hepatitis C
Active hepatitis B or hepatitis C with abnormal liver function tests
Recent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitis
Active hepatitis B or hepatitis C
Must have Child-Pugh A only. Participants may have any viral status (hepatitis B, hepatitis C, or none).
Subject with seropositivity for hepatitis B or hepatitis C must be cleared by hepatology service prior to participating in treatment protocol
Patients with known hepatitis B or C; screening for hepatitis B and/or C is not required for eligibility for this study
Active hepatitis B or hepatitis C
Hepatitis B or C
Active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus RNA detectable)
Hepatitis B or C
Active hepatitis B or hepatitis C
Active hepatitis A, hepatitis B, or hepatitis C infection
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Active hepatitis B, hepatitis C at the time of screening
Active hepatitis B, hepatitis C at the time of screening
Active hepatitis A, hepatitis B, or hepatitis C infection
Patients who are carriers of hepatitis virus B and C; hepatitis B and C testing must be performed to confirm status prior to enrollment
Patients who are carriers of hepatitis B will be included in this study
Known hepatitis B or hepatitis C with abnormal liver function tests
All participants will be required to be screened for hepatitis C; if hepatitis C antibody positive, with or without a positive hepatitis C RNA level, participants will be permitted to enroll in the study provided liver function tests meet criteria listed, and have no evidence of cirrhosis; participants diagnosed with hepatitis C less than  months from trial enrollment will be considered to have acute hepatitis C, and will be excluded from study UNLESS hepatitis C viral load is undetectable
On treatment for hepatitis B or hepatitis C or history of tuberculosis (TB)
Active tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis
Hepatitis C on protease therapy
Active hepatitis B or hepatitis C treatment
Has known hepatitis B or hepatitis C
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Patients with active hepatitis B or C infection (not including patients with prior hepatitis B vaccination); these patients should be cleared by gastrointestinal (GI) consultation for hepatitis B and infectious disease consult for hepatitis C
Active hepatitis B or hepatitis C with abnormal liver function tests; HIV positive patients receiving antivirals.
Baseline hepatitis titers without evidence of acute/active hepatitis
Has autoimmune hepatitis
Active hepatitis B, hepatitis C
Patients with clinical symptoms of hepatitis B and/or hepatitis C will be tested, if clinically indicated per medical records review; if no indications exist in clinical evaluation or laboratory values that are consistent with hepatitis, patients will not be routinely tested for hepatitis B virus (HBV)/hepatitis C virus (HCV); positive results will be an exclusion criteria
Hepatitis B and C negative
Seropositive for any of the following: HIV ab, hepatitis B sAg, hepatitis (hep) C immunoglobulin (Ig)G Ab positive, without definitive therapy for hepatitis C; or hepatitis C PCR positivity; or hepatitis C IgM positivity
Patients who have any known history of liver disease, autoimmune hepatitis, sclerosing cholangitis or are found to be carriers (active disease or not) of hepatitis B and hepatitis C
Active viral hepatitis or autoimmune hepatitis; the work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretion
Active hepatitis B or hepatitis C with abnormal liver function tests
Patients with hepatitis C antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitis
Patients with evidence of hepatitis B or hepatitis C PCR positivity
Active hepatitis including hepatitis B or C
Patients with hepatitis B
Current or active tuberculosis, hepatitis B, or hepatitis C.
Active coinfection with both hepatitis B (i.e., HBVsAg and/or hepatitis B DNA) and hepatitis C (i.e., hepatitic C RNA)
Hepatitis D infection in subjects with hepatitis B
Active hepatitis B, hepatitis C, or tuberculosis
Baseline hepatitis tiers without evidence of active hepatitis
Active hepatitis B or hepatitis C
Active or latent virus disease (HIV, hepatitis B and hepatitis C)
Active hepatitis B or hepatitis C
Patients with active hepatitis B or C. Screening for hepatitis B Prior to randomization/start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBsAg, HBcAb, HBsAb and quantitative hepatitis B DNA PCR (HBV-DNA):  All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece. [http://wwwnc.cdc.gov/travel/yellowbook//chapter--infectious-diseases-related-to-trave l/hepatitis-b.htm]
A risk of reactivation of hepatitis B or C.
Active Hepatitis B or hepatitis C
Individuals with active hepatitis B or C are ineligible
Individuals with active uncontrolled hepatitis B or C are ineligible
All patients must be willing to be tested for hepatitis screening; patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above; patients must be followed by a hepatologist during the course of this study
Active hepatitis B or hepatitis C with abnormal liver function tests.
Active hepatitis B or hepatitis C
Hepatitis B or C
Hepatitis B or C
Subjects with acute hepatitis
Active hepatitis B or hepatitis C
Subjects with confirmed Hepatitis A, B or C
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Participants with active hepatitis B, hepatitis C, or tuberculosis
Active hepatitis B or hepatitis C with abnormal liver function tests.
Patients with active hepatitis B or hepatitis C are excluded
History of hepatitis B or C infection (subjects with evidence of cleared hepatitis B are permitted).
Patients must have negative hepatitis C virus (HCV) serology; all patients must be screened for hepatitis B infection before starting treatment; those patients who test positive for hepatitis B should be closely monitored for evidence of active hepatitis B virus (HBV) infection and hepatitis during and for several months after rituximab treatment; PCNSL patients with a history of hepatitis B infection should be treated with entecavir or lamivudine (physician discretion for choice of drug) as antiviral prophylaxis to prevent hepatitis B reactivation
Known active hepatitis, a history of viral hepatitis B or hepatitis C
Known hepatitis B or hepatitis C infection or liver cirrhosis
Detectable Hepatitis C virus (indicative of active Hepatitis C)
Has a known history of active hepatitis B or C. Healthy carriers of hepatitis B are not allowed on this study
Patients with hepatitis B and C will be excluded
Patients with hepatitis
Active hepatitis B or C, but participants on stable medications for hepatitis B or C.
Patients known to be seropositive for hepatitis C hepatitis B
Uncontrolled Hepatitis B despite appropriate therapy.
History of HIV, hepatitis B, or hepatitis C
Patients with current evidence of hepatitis A, B, or C (i.e., active hepatitis)
Active hepatitis B, hepatitis C
Hepatitis B or C.
Active hepatitis B or hepatitis C
Patients with hepatitis B and hepatitis C must be under the care of viral hepatitis expert consultant; patients with hepatitis B are required to be treated with anti-hepatitis B virus (HBV) treatment (e.g., entecavir); patients with hepatitis C need to have received prior and/or ongoing hepatitis C treatment
Active hepatitis B or hepatitis C
